Diagnosis: EGFR inhibitor papulopustular eruption
A 54-year-old female presented with an acneiform eruption on the face and upper trunk two weeks after initiating cetuximab for metastatic colorectal cancer. The eruption was characterized by erythematous papules and pustules, resembling acne vulgaris, prompting evaluation for drug-related cutaneous toxicities.
A 54-year-old female with a history of metastatic colorectal cancer presented two weeks after starting cetuximab, complaining of a sudden onset of facial and upper trunk eruptions. On examination, the patient exhibited multiple erythematous papules and pustules predominantly on the face and upper chest, with some areas of dryness and scaling. There were no signs of cystic lesions or nodules typically associated with acne vulgaris.Location: Face and upper trunkLesion type: Erythematous papules and pustulesAssociated symptoms: Mild pruritusOnset: Two weeks post-treatment initiationNo prior history: Acne vulgaris or similar eruptions
The patient reported that the eruption began approximately two weeks after her first dose of cetuximab. Prior to this treatment, she had no significant dermatologic history or similar drug reactions. She was previously treated with chemotherapy and had no known drug allergies. The patient lives alone, does not smoke, and has no pets. She has a family history of breast cancer but no other significant familial dermatologic conditions.Onset: Eruption started two weeks after cetuximab initiationPrior treatments: Previous chemotherapy with no dermatologic side effectsRelevant history: No history of acne or similar skin conditionsSocial history: Non-smoker, lives aloneFamily history: Notable for breast cancer, no other dermatologic conditions
Acute / First-Line ManagementDiscontinuation of cetuximab may be considered if the eruption is severe.Topical therapies such as clindamycin gel or benzoyl peroxide may be applied to affected areas twice daily.Oral doxycycline 100 mg twice daily can be initiated for moderate to severe cases.Consideration of oral isotretinoin in persistent cases, starting at 0.5 mg/kg/day, may be warranted.Workup and Diagnostic ConfirmationClinical diagnosis based on characteristic eruption and timing of cetuximab initiation.Consider skin biopsy if lesions are atypical or unresponsive to treatment.Laboratory tests may be performed to rule out infectious etiologies.Long-Term ManagementRegular follow-up to monitor for recurrence or new lesions following adjustment of therapy.Patient education regarding the potential for cutaneous toxicities with EGFR inhibitors.Dermatology referral for persistent or severe cases not responding to initial management.
Acne vulgaris: Typically presents with comedones, cysts, and may involve the back and shoulders; not associated with recent chemotherapy.Folliculitis: Presents as pustules that may be centered around hair follicles; often itchy and may have associated discomfort.Drug-induced lupus erythematosus: Can present with facial eruptions, but usually associated with systemic symptoms such as arthralgia or fatigue.Rosacea: Characterized by flushing, telangiectasia, and inflammatory papules, but typically has a more chronic course and distinct triggers.Perioral dermatitis: Often localized around the mouth and nose, presenting with papules and pustules; associated with topical corticosteroid use.Contact dermatitis: Eruption may be localized to areas of contact with allergens or irritants, and typically associated with itching and scaling.Keratosis pilaris: Presents as small, rough bumps on the skin, not typically inflamed or pustular.Herpes simplex virus infection: May present with vesicles and crusting; typically painful and has a prodromal phase.
High-Yield PearlsEGFR inhibitors: Commonly associated with cutaneous toxicities, including papulopustular eruptions.Timing: Eruptions can occur within two weeks of initiation, emphasizing the need for early recognition.Management: Topical and systemic therapies can effectively manage symptoms; early intervention may prevent worsening.Patient education: Important to inform patients about potential skin side effects to enhance adherence to treatment.Referral: Dermatology consultation is advisable for severe or persistent eruptions that do not respond to first-line management.Recognizing and managing cutaneous toxicities early can significantly improve patient quality of life during EGFR inhibitor therapy.
Tags: EGFR inhibitor, drug reaction, papulopustular